Yesterday, members of the PureTech and Gallop Oncology teams participated in #MoveForMDS Boston in support of patients and families affected by #myelodysplasticsyndromes (MDS). We are proud to join the @MDSFoundation and the local MDS community to raise awareness and support continued progress for those impacted by this disease. Thank you to everyone who made it such a meaningful day!

The Gallop Oncology team will be onsite at #ESMO26, where Phase 1b results for LYT-200 will be presented in an oral proffered paper session. Guenther Koehne, MD, PhD, will highlight encouraging clinical activity and favorable safety observed in heavily pretreated patients with relapsed/refractory high-risk #MyelodysplasticSyndromes and #AcuteMyeloidLeukemia. These findings reinforce the potential of LYT-200 as a first-in-class, mutation-agnostic treatment option. Learn more about the upcoming presentation and Gallop’s plans to advance LYT-200 into Phase 2 development: bit.ly/4dKKqEd

We’re honored to be shortlisted for the 2026 @Citeline Biotech Awards in the category of Excellence in Rare Disease Drug Development. This recognition reflects our work advancing deupirfenidone, an investigational, next-generation antifibrotic with the potential to serve as a new standard of care for people living with #idiopathicpulmonaryfibrosis (#IPF). Deupirfenidone is now being advanced by our Founded Entity @CeleaTx through SURPASS-IPF: the first industry-sponsored head-to-head Phase 3 trial in IPF, which is evaluating the potential superiority of deupirfenidone against an approved antifibrotic. Congratulations to our fellow shortlisted companies on this recognition. We’re inspired by the breadth of scientific innovation represented and the shared commitment to advancing #raredisease treatments through close collaboration with patients, clinicians, and advocacy communities. Read more about the 2026 Citeline Biotech Awards: bit.ly/4dyaAtS

Today we announced our 2026 Half-Year results & will host a webcast at 9am BST. Read more: bit.ly/46COB0Y

Today, we announced two important milestones for LYT-200: Successful End-of-Phase 1 meeting with the FDA FDA Fast Track designation for R/R high-risk #MyelodysplasticSyndromes These achievements support advancement into the Phase 2 STRIDE-MDS trial. bit.ly/4yPOjjj #HRMDS

We’re honored to be nominated for a 2026 #PrixGalien USA Award in the Incubators, Accelerators and Equity category. This recognition reflects the strength of the model we have built at PureTech to identify high-potential therapeutic opportunities, advance and de-risk them, and form dedicated companies around the most promising programs – all with the goal of bringing important new medicines to patients. We’re proud that this approach has generated a portfolio of companies and dozens of therapeutic candidates, including three that have received FDA approval. Thank you to @GalienFdn for including us among this distinguished group of nominees. prn.to/4ci9pOk

Just days after announcing the financing for our Founded Entity @CeleaTx, we're pleased to share another important milestone. The first patient has been dosed in SURPASS-IPF, the first industry-sponsored head-to-head Ph3 trial in #idiopathicpulmonaryfibrosis, evaluating deupirfenidone. Read more: bit.ly/4w2ibYN

Today marks an important milestone for PureTech and our Founded Entity @CeleaTx. We have launched Celea with a $180 million financing from a distinguished syndicate of leading healthcare investors to advance deupirfenidone. The financing enables the planned initiation of SURPASS-IPF, the first-ever industry-sponsored head-to-head Phase 3 trial in #idiopathicpulmonaryfibrosis (#IPF). Read more: bit.ly/3RgLeZk

We have built a model designed to repeatedly create, advance, & fund innovative therapeutic programs - an approach that has contributed to 3 FDA approvals & the creation of multiple Founded Entities (Seaport Therapeutics, Celea Therapeutics, Gallop Oncology, & more) Our CEO Rob Lyne and President & Co-Founder Eric Elenko recently joined the Base to Base Biotech podcast to discuss the evolution of that model, recent portfolio progress, and the many catalysts ahead. Listen here: bit.ly/43HpaJW PureTech interview begins at 31:56

Join us at #ATS2026! We’ll detail SURPASS-IPF (first industry-sponsored, head-to-head, Ph3 superiority #IPF trial) & insights on the translatability of our Ph2b data. So proud of our Celea colleagues who are advancing deupirfenidone as a potential new SOC bit.ly/4nm7a0I

Today we announced our 2025 Full Year Results and Annual Report, highlighting continued progress across our Portfolio with a sharpened strategic focus on disciplined capital allocation, operational efficiency, & long-term value creation. Join us at 9AM EDT/2PM BST as we discuss how PureTech is positioned for the future bit.ly/3R7xJL2

We’re pleased to share positive topline data from Ph1b trial of LYT-200 in relapsed/refractory (R/R) high-risk #MyelodysplasticSyndrome & R/R #AcuteMyeloidLeukemia. Our Founded Entity, Gallop Oncology, intends to discuss next steps w/ FDA in R/R HR-MDS. bit.ly/4mMpnVd

Now published in @ATSBlueEditor: full results from the Phase 2b ELEVATE IPF trial of deupirfenidone These results provide a strong scientific & clinical foundation as our Founded Entity, Celea Therapeutics, prepares to advance deupirfenidone into Phase 3. bit.ly/47Di0sM #idiopathicpulmonaryfibrosis #ipf

Today our Founded Entity @SeaportTx announced the publication of a manuscript that captures the discovery process behind the creation of GlyphAllo, further validating the Glyph platform. Initially advanced at PureTech, GlyphAllo is a hallmark of our strategy of identifying clinically validated pharmacology and overcoming key limitations through targeted innovation.

On #RareDiseaseDay, the world recognizes & supports those living w/ #rarediseases. At PureTech, this is our focus every day. Today, our team joined @Cycle4Survival to champion rare cancer research – an extension of our work at Gallop Oncology to advance LYT-200 in #AML. The same commitment drives our team at Celea Therapeutics to advance deupirfenidone for pp w/ #IPF. Both programs received Orphan Drug Designation, reflecting the need in these communities & what drives us to deliver on our mission .